|
|
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
|
|
|
- Stock prices approach a strong long-term resistance in weekly data at USD 91.12.
- Technically, the stock approaches a strong medium-term resistance at USD 89.02.
- The company is in debt and has limited leeway for investment
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
- The company's enterprise value to sales, at 4.79 times its current sales, is high.
|
|
|
|
|
| Sector Pharmaceuticals - NEC |
|
| | 1st jan. | Capitalisation (M$) | Investor Rating |
 |
 | ABBVIE | -5.65% | 128 628 | |
| |
|
|
|
|
AstraZeneca shares rise on early U.S. approval for leukaemia drug |
| Sales 2019 |
33 293 M |
| EBIT 2019 |
15 768 M |
| Net income 2019 |
8 578 M |
| Debt 2019 |
30 704 M |
| Yield 2019 |
4,94% |
|
| P/E ratio 2019 |
14,6x |
| P/E ratio 2020 |
10,1x |
| EV / Sales2019 |
4,79x |
| EV / Sales2020 |
4,05x |
| Capitalization |
129 B |
|
Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
|
| Finances |
|
| Profitability |
|
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
|
| Potential |
|
| Yield |
|
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report 
